Full-Time

Executive Director Strategic Project Leader

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

No salary listed

Expert

Ireland

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Supply Chain Management
Requirements
  • BA or BS degree in Engineering, Chemistry, Supply Chain or another relevant field.
  • 15+ combined years of experience in Manufacturing, Contract Manufacturing, Technical Operations, Supply Chain or Quality.
  • Direct experience in small molecule Drug Substance, Drug Product and Finish Pack manufacturing supporting both clinical and commercial products.
  • International CMO management experience.
  • Excellent written and oral communication and presentation skills.
  • Strong problem solving, decision making, planning, analytical and project management skills.
  • Excellent hands-on Change Management experience demonstrated through strong cross functional collaboration and partnership.
  • Ability to travel approximately 25%.
  • Solid understanding of pharmaceutical development, manufacturing, packaging, and labeling.
  • Demonstrated strong communication and collaboration skills with team members across functions including but not limited to clinical operations, manufacturing, commercial, finance, procurement, IT.
  • Demonstrated proficiency in supply strategy development, influencing, teamwork, enterprise thinking, relationship management, financial foresight, product costing and business case development.
  • A comprehensive understanding of product development, manufacturing and supply management and how other functions contribute to achieving the Supply Chain objectives of the business.
  • Demonstrated success working cross-functionally and influencing to senior levels of the organization.
  • Detailed knowledge of lean as it applies to supply chains.
  • Demonstrated understanding of global, regional and local environments to identify risks, and design robust supply chains that deliver product in the real world.
  • A detailed understanding of the pharmaceutical or broader healthcare/FMCG industries and an understanding of the global context and its application to business opportunities.
  • Previous experience in a supply-chain management or related role.
  • Previous experience in at least two operations, or product development roles/functions.
Responsibilities
  • Apply knowledge and expertise to design, establish and optimize product supply chains throughout the lifecycle for a portfolio of products within a Therapy Area.
  • Provide product/brand leadership to other senior leaders within Operations and represent Operations and product supply on Commercial Brand Teams and in other senior product partner forums.
  • Optimize performance of current supply chains including using lean methodologies to improve supply chain lead-time.
  • Work across GSC&TO to deliver end-to-end Supply Chain operational performance critical metrics and support initiatives to optimize inventory.
  • Own and manage the product business continuity plans for the products and ensure a constant state of readiness to ensure product supply.
  • Lead and advise a matrixed supply chain team to complete the product strategy and deliver key supply chain changes.
  • Deliver successful, seamless, timely new product launches to parameters agreed with the LCT.

Cytokinetics focuses on developing medicines to improve muscle function for patients with cardiovascular and neuromuscular diseases, such as heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company creates small molecule drugs that either enhance or inhibit muscle function based on the specific needs of the condition being treated. Its product pipeline includes several drugs currently in clinical trials, such as omecamtiv mecarbil and reldesemtiv. Cytokinetics distinguishes itself from competitors by its dedicated focus on muscle-related diseases and its extensive experience in conducting clinical trials. The company's goal is to bring effective treatments to market that address the unmet medical needs of patients suffering from debilitating muscle conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine aligns with Cytokinetics' tailored treatment approach.
  • AI in drug discovery could enhance Cytokinetics' R&D efficiency and reduce time to market.
  • FDA initiatives expedite approval for rare disease drugs, benefiting Cytokinetics' pipeline.

What critics are saying

  • Increased competition from Imbria Pharmaceuticals may impact Cytokinetics' market share.
  • Sanofi's rights to Aficamten in Greater China may limit Cytokinetics' market access.
  • Public offering at $51/share may dilute existing shareholder value and affect stock performance.

What makes Cytokinetics unique

  • Cytokinetics focuses on first-in-class muscle activators and next-in-class muscle inhibitors.
  • The company targets cardiovascular and neuromuscular diseases with unmet medical needs.
  • Cytokinetics has a robust pipeline including omecamtiv mecarbil and reldesemtiv.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
GlobeNewswire
Apr 10th, 2025
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA...

Here Novi
Mar 21st, 2025
Cytokinetics Launches EARTH-HCM for Hypertrophic Cardiomyopathy Awareness

Cytokinetics launches EARTH-HCM for hypertrophic cardiomyopathy awareness.

Investing.com
Mar 20th, 2025
Cytokinetics launches interactive HCM public health tool

Cytokinetics launches interactive HCM public health tool.

Medical Update Online
Mar 19th, 2025
Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025

Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025.

Stock Titan
Jan 6th, 2025
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.